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1.Introduction
In a drug development process, the primary goal of Phase II clinical trials is to determine whether there is sufficient evidence of efficacy and safety to make it worth further study in a Phase III clinical trial.
For example, suppose a new drug is developed for patients with liver cancer. To investigate whether this new drug extends the life of liver cancer patients, the criterion of drug efficacy is defined to be the presence of tumor shrinkage, which is a binary endpoint with response probability p. In a single-stage design, if the number of patients with tumor shrinkage is large enough, then this new drug may be used as evidence for further testing.
Most often, drug experiments employ a Simon's two-stage design [1] in order to avoid giving patients an ineffective drug. Suppose there are n 1 patients participating in the first-stage experiment, and there are n 2 additional patients participating in the second-stage experiment if the new drug design is allowed to continue. The number of responses Y 1 is observed at the first stage, and if Y 1 is less than a specified value a, the design is stopped. Otherwise, this drug design is allowed to continue and the number of responses Y 2 , which is independent of Y 1 , is observed at the second stage.
Consequently, the response probability of patients with tumor shrinkage is to be estimated in order to plan a further study.
It is natural to use sample proportion to estimate p. However, when the second stage is allowed to continue, this estimator will overestimate the true p, because the number of responses at the first stage is truncated by a and follows a truncated binomial distribution. Therefore, a maximum likelihood estimator based on the truncated binomial distribution is derived to take into account the truncation effect. In addition, to take into account the inherent variability of patients in the measured responses, the confidence interval, that is a range of feasible values within which the true p may lie, is also constructed for p. Two types of interval estimators, the Wald interval without (with) continuity correction [2] and the score interval without (with) continuity correction [3] , are constructed in the next section.
2.The proposed method
When the second stage is allowed to continue, the possible values of Y 1 are truncated by a, so the probability distribution of Y 1 is referred to as truncated binomial distribution with response probability p and its probability mass function is with While the probability distribution of Y 2 is binomial with the same response probability p, and its probability mass function is . Because a discrete random variable can take on only specified values, the correction for continuity adjustment, 1/(2(n-a)), is employed. The resulting Wald interval with continuity correction (Wald_c) is denoted by +1/(2 (n-a)) Following Wilson's [3] concept, the lower and upper limits of the score confidence interval without (with) continuity correction can also be solved by replacing with the actual success probabilityp. So for given , the lower and upper limits of the score interval are the solution to the equations and respectively. The resulting confidence interval (Score) is denoted by . Similarly, the score interval with continuity correction (Score_c) is denoted by .
3.Comparison results
The evaluation criteria for comparing the performance of interval estimators are the actual coverage probability and the expected width of an interval estimator, which is defined as CP(p)=∑I(x,p)P (X=x) and EW(p) = , respectively, where I(x, p) is an indicator with 1 if the interval based on X=x contains p, and 0 if it does not contain p and is the width of an interval estimate.
Note that the length of confidence interval measures the precision of estimation, and it is desirable to obtain a confidence interval that is short enough with adequate confidence (or coverage probability).
In Phase II clinical trials, the investigators are asked to specify the largest (smallest) success probability, p 1 (p 0 ), which, if true, would clearly imply that the treatment is (is not) promising for further study. For given p 0 , p 1 , α, and β (type II error rate), Table I displays the actual coverage probabilities and the expected width. In this sense, the maximum likelihood estimator of p is slightly underestimated and the sample proportion is overestimated. When n 1 is considerably larger than n 2 , for example, n 1 =34 and n 2 =5, the maximum likelihood estimator underestimates significantly the true p and the coverage probability of the score interval without continuity correction is considerably lower than the nominal confidence level which is 0.95 in this comparison. Although the expected interval width of the score interval without continuity correction is almost the smallest, the difference between the expected interval widths of two score interval estimators is negligible. Therefore, according to the mean coverage probability and expected interval width, this paper recommended the score interval with continuity correction for estimating p based on the data from Simon's two-stage designs. 
